Das Reizdarmsyndrom – eine Fehlbezeichnung?

Literatur

• 1 GFK Marktforschung Nürnberg . Die 100 wichtigsten Krankheiten. Woran die Deutschen nach Selbsteinschätzung leiden.  Apothekenumschau. 2006;  1
• 2 Layer P, Andresen V, Pehl C et al. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnistik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM).  Z Gastroenterol. 2011;  49 237-293
• 3 Whitehead W E, Crowell M D, Bosmajin L et al. Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples.  Gastroenterology. 1990;  98 336-340
• 4 Taub E, Cuevas J L, Cook I II EW et al. Irritable bowel syndrome defined by factor analysis: gender and race comparisons.  Dig Dis Sci. 1995;  40 2647-2655
• 5 Kay L, Jorgensen T. Redefining abdominal syndromes. Results of population-based study.  Scan J Gastroenterol. 1996;  31 469-475
• 6 Schlemper R J, Van der Werf S DJ, Vandenbrouke J P et al. Peptic ulcer, non-ulcer dyspepsia and irritable bowel syndrome in the Netherlands and Japan.  Scan J Gastroenterol. 1993;  28 (Suppl 200) 33-41
• 7 Robbins J M, Kirmayer L J, Hemami S. Latent variable models of functional somatic distress.  J of Nervous and Mental Diseases. 1997;  185 606-615
• 8 Talley N J, Holtmann G, Agréus L et al. Gastrointestinal symptoms and subjects cluster into distinct upper and lower groupings in the community: a four nations study.  Am J Gastroenterol. 2000;  95 1439-47
• 9 Agreus L, Svardsudd K, Nyren 0 et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time.  Gastroenterology. 1995;  109 671-680
• 10 Yale S H, Musana K, Kieke A et al. Applying case definition criteria to irritable bowel syndrome.  Clin Med and Res. 2008;  6 9-16
• 11 Chang J Y, Talley N J. An update on irritable bowel syndrome: from diagnosis to emerging therapies.  Curr Opin Gastroenterol. 2011;  27 72-78
• 12 Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome.  Gastroenterology. 2007;  132 26-37
• 13 Cenac N, Andrews C N, Holzhausen M et al. Role for protease activity in visceral pain in irritable bowel syndrome.  J Clin Invest. 2007;  117 636-47
• 14 Buhner S, Li Q, Vignali S et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome.  Gastroenterology. 2009;  137 1425-1434
• 15 Corinaldesi R, Stanghellini V, Cremon C et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study.  Aliment Pharmacol Ther. 2009;  30 245-252
• 16 Klooker T K, Braak B, Koopman K E et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome.  Gut. 2010;  59 1213-1221
• 17 Spiller R, Garsed K. Postinfectious irritable bowel syndrome.  Gastroenterology. 2009;  136 (6) 1979-1988
• 18 Walker M M, Talley N J, Prabhakar M et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia.  Aliment Pharmacol Ther. 2009;  29 765-773
• 19 Guilarte M, Santos J, Torres de I et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum.  Gut. 2007;  56 203-209
• 20 Molderings G J, Homann J, Raithel M et al. Toward a global classification of mast cell activation diseases.  J Allergy Clin Immunol. 2011;  DOI: 10.1016/j.jaci.2010.12.1113
• 21 Frieling T, Meis K, Kolck U W et al. Evidence for Mast Cell Activation in Patients with Therapy-Resistant Irritable Bowel Syndrome.  Z Gastroenterol. 2011;  49 191-194
• 22 Homann J, Kolck U W, Ehnes A et al. Die systemische Mastozytose – Standortbestimmung einer internistischen Erkrankung.  Med Klin. 2010;  105 544-53